Abstract
AbstractA 6-month-old girl, previously diagnosed with cystic fibrosis (CF), was admitted to hospital for nephrolithiasis. Her parents were first-degree cousins. The patient underwent endoscopic stone management. Despite no family history of stones and medical treatment with potassium citrate, the patient developed recurrent renal stones and atypical urinary tract infections during follow-up. Basic investigations were all normal. Due to consanguinity and early presentation of nephrolithiasis, metabolic causes such as cystinuria and hyperoxaluria were considered. Cystinuria was excluded due to normal cystine levels. High urinary oxalate excretion was found as expected due to absorptive (secondary) hyperoxaluria in CF patients. An early stone burden in the patient with a history of medical treatment and consanguinity led us to perform a genetic testing. Genetic testing revealed a missense homozygous variant in exon 1 of the AGXT gene. The patient was diagnosed with primary hyperoxaluria type 1. Two rare life-threatening genetic diseases were found together in the same child.
Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Singh P, Harris PC, Sas DJ, Lieske JC (2022) The genetics of kidney stone disease and nephrocalcinosis. Nat Rev Nephrol 18:224–240
2. Esfandiar N, Khanbabaee G, Riazi Kermani K (2020) Urinary system and renal ınvolvement in children with cystic fibrosis. Iran J Kidney Dis 14:278–281
3. Knauf F, Thomson RB, Heneghan JF, Jiang Z, Adebamiro A, Thomson CL, Barone C, Asplin JR, Egan ME, Alper SL, Aronson PS (2017) Loss of cystic fibrosis transmembrane regulator ımpairs ıntestinal oxalate secretion. J Am Soc Nephrol 28:242–249
4. Hoppe B, von Unruh GE, Blank G, Rietschel E, Sidhu H, Laube N, Hesse A (2005) Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis. Am J Kidney Dis 46:440–445
5. Gang X, Liu F, Mao J (2023) Lumasiran for primary hyperoxaluria type 1: what we have learned? Front Pediatr 10:1052625